糖蛋白特异性直接血小板自身抗体检测在免疫性血小板减少症中的现代再评估
本研究严格遵循2011年ASH的ITP诊断标准和2012年ISTH的血小板自身抗体检测建议,回顾性分析了368例成人ITP患者的485次检测。阳性结果诊断活动性ITP的敏感性和特异性分别为90%和78%,阴性结果确认临床缓解的敏感性和特异性分别为87%和91%。自身抗体靶向的糖蛋白数量越多,疾病越严重,但血清学检测不能预测治疗反应。
要点
- 按ISTH建议行糖蛋白特异性直接PA检测,诊断活动性ITP敏感性90%、特异性78%。
- 阴性结果确认临床缓解的敏感性87%、特异性91%。
- 自身抗体靶向糖蛋白数每增加一个,重症和难治性ITP风险分别增加2.27倍和3.09倍。
核心结论
- 按ISTH建议行糖蛋白特异性直接PA检测,在符合ASH诊断标准的ITP患者中对诊断和确认缓解具有敏感性和特异性。
- 自身抗体靶向的糖蛋白数量越多,提示疾病越严重。
研究设计与样本
- 回顾性研究,共986次PA检测,其中368例患者的485次检测符合标准并纳入分析。
- 严格应用2011年ASH的ITP诊断标准和2012年ISTH的PA检测建议。
主要发现
- 阳性结果诊断活动性ITP(228例)的敏感性90%、特异性78%。
- 阴性结果确认临床缓解(61次检测)的敏感性87%、特异性91%。
- 存在抗GPIIb/IIIa和抗GPIb/IX抗体是ITP患者出现抗GPIa/IIa抗体的必要条件。
- 血清学检测不能有意义地预测对糖皮质激素、静脉免疫球蛋白或血小板生成素受体激动剂的治疗反应。
关键数值与推荐
- 活动性ITP诊断:阳性PA检测敏感性90%、特异性78%(n=228例)。
- 临床缓解确认:阴性PA检测敏感性87%、特异性91%(n=61次检测)。
临床怎么用
- 对符合ASH诊断标准的成人ITP患者,可按ISTH建议行糖蛋白特异性直接PA检测辅助诊断和确认缓解。
- PA检测结果不宜用于预测对糖皮质激素、IVIG或TPO-RA的治疗反应。
局限性
- 回顾性研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Platelet autoantibody (PA) testing has previously shown poor sensitivity for immune thrombocytopenia (ITP) diagnosis, but no previous study used both 2011 American Society of Hematology (ASH) guidelines for ITP diagnosis and 2012 International Society on Thrombosis and Haemostasis (ISTH) PA testing recommendations. We therefore performed a comprehensive retrospective study of PA testing in adult patients with ITP strictly applying these criteria. Of 986 PA assays performed, 485 assays in 368 patients met criteria and were included. Sensitivity and specificity of a positive test result for diagnosis of active ITP (n = 228 patients) were 90% and 78%, respectively. Sensitivity and specificity of a negative test result for clinical remission (n = 61 assays) were 87% and 91%. Antibodies against both glycoprotein IIb (GPIIb)/IIIa and GPIb/IX were required for the presence of antibodies against GPIa/IIa in patients with ITP. Logistic regression analysis revealed that more positive autoantibodies predicted more severe disease (relative to nonsevere ITP, relative risk ratio for severe ITP and refractory ITP was 2.27 [P < .001] and 3.09 [P < .001], respectively, per additional autoantibody); however, serologic testing did not meaningfully predict treatment response to glucocorticoids, intravenous immunoglobulin, or thrombopoietin receptor agonists. Sixty-four patients with ITP had multiple PA assays performed longitudinally: all 10 patients achieving remission converted from positive to negative serologic results, and evidence for epitope spreading was observed in 35% of patients with ongoing active disease. In conclusion, glycoprotein-specific direct PA testing performed using ISTH recommendations in patients meeting ASH diagnostic criteria is sensitive and specific for ITP diagnosis and reliably confirms clinical remission. More glycoproteins targeted by autoantibodies predicts for more severe disease.
引用
- Al-Samkari H, Rosovsky RP, Karp Leaf RS, et al. A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia. Blood Adv. 2020. PMID: 31891657. doi:10.1182/bloodadvances.2019000868
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。